Cargando…

Long-term relationship between everolimus blood concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma: a prospective study

BACKGROUND: Everolimus is an oral inhibitor of mammalian target of rapamycin, approved for metastatic renal cell carcinoma (mRCC). Recently, personalized medicine through therapeutic drug monitoring (TDM) is recommended in cancer therapy. In this study, the relationship between everolimus blood conc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takasaki, Shinya, Yamaguchi, Hiroaki, Kawasaki, Yoshihide, Kikuchi, Masafumi, Tanaka, Masaki, Ito, Akihiro, Mano, Nariyasu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413453/ https://www.ncbi.nlm.nih.gov/pubmed/30906563 http://dx.doi.org/10.1186/s40780-019-0135-5

Ejemplares similares

Severe toxicity induced by accumulation of active sunitinib metabolite in a Japanese patient with renal cell carcinoma: a case report
por: Takasaki, Shinya, et al.
Publicado: (2017)

Comparison of PETINIA and LC-MS/MS for determining plasma mycophenolic acid concentrations in Japanese lung transplant recipients
por: Kikuchi, Masafumi, et al.
Publicado: (2018)

Predictive model for recurrence of renal cell carcinoma by comparing pre‐ and postoperative urinary metabolite concentrations
por: Morozumi, Kento, et al.
Publicado: (2021)

Enhancement and evaluation of a prescription audit system for direct oral anticoagulants using a check sheet
por: Ishikawa, Naoto, et al.
Publicado: (2021)

Metabolomic Analysis to Elucidate Mechanisms of Sunitinib Resistance in Renal Cell Carcinoma
por: Sato, Tomonori, et al.
Publicado: (2020)

Accurate quantification of urinary metabolites for predictive models manifest clinicopathology of renal cell carcinoma
por: Sato, Tomonori, et al.
Publicado: (2020)

Bile Acid–Drug Interaction via Organic Anion-Transporting Polypeptide 4C1 Is a Potential Mechanism of Altered Pharmacokinetics of Renally Excreted Drugs
por: Yamauchi, Minami, et al.
Publicado: (2022)

High throughput LC/ESI-MS/MS method for simultaneous analysis of 20 oral molecular-targeted anticancer drugs and the active metabolite of sunitinib in human plasma
por: Hirasawa, Tensei, et al.
Publicado: (2023)

Transport of Eicosapentaenoic Acid-Derived PGE(3), PGF(3α), and TXB(3) by ABCC4
por: Tanaka, Nobuaki, et al.
Publicado: (2014)

Stimulatory effect on the transport mediated by organic anion transporting polypeptide 2B1
por: Ogura, Jiro, et al.
Publicado: (2020)

Everolimus pharmacokinetics and exposure-response relationship in Japanese patients with advanced breast cancer
por: Hirabatake, Masaki, et al.
Publicado: (2022)

Immunological effects of everolimus in patients with metastatic renal cell cancer
por: Huijts, Charlotte M, et al.
Publicado: (2017)

Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma
por: Rossetti, Sabrina, et al.
Publicado: (2017)

Phase III Trial of Everolimus in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from RECORD-1
por: Tsukamoto, Taiji, et al.
Publicado: (2011)

Itraconazole Contaminated with Rilmazafone in Japan: A Retrospective Analysis Using the Japanese Adverse Drug Event Report Database
por: Tsuchiya, Masami, et al.
Publicado: (2022)

Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma
por: Bendtsen, Mathias Alrø Fichtner, et al.
Publicado: (2017)

Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results
por: Takahashi, Kota, et al.
Publicado: (2013)

Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies
por: Grünwald, V, et al.
Publicado: (2011)

Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
por: Molina, Ana M., et al.
Publicado: (2010)

Metabolic Alteration Analysis of Steroid Hormones in Niemann–Pick Disease Type C Model Cell Using Liquid Chromatography/Tandem Mass Spectrometry
por: Abe, Ai, et al.
Publicado: (2022)

Everolimus in the Treatment of Metastatic Breast Cancer
por: Royce, Melanie E, et al.
Publicado: (2015)

Everolimus for Advanced Pancreatic Neuroendocrine Tumours: A Subgroup Analysis Evaluating Japanese Patients in the RADIANT-3 Trial
por: Ito, Tetsuhide, et al.
Publicado: (2012)

Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report
por: Katsumata, Yuki, et al.
Publicado: (2021)

Preference of Conjugated Bile Acids over Unconjugated Bile Acids as Substrates for OATP1B1 and OATP1B3
por: Suga, Takahiro, et al.
Publicado: (2017)

Effects of an evidence-based medicine workshop on Japanese pharmacy students’ awareness regarding the importance of reading current clinical literature
por: Nakagawa, Naoto, et al.
Publicado: (2015)

FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer
por: Chen, James L, et al.
Publicado: (2013)

Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma
por: Ismayilov, Rashad, et al.
Publicado: (2022)

Characteristics of Adverse Events Following Immunization Reporting in Children: The Japanese Adverse Drug Event Report Database
por: Noda, Aoi, et al.
Publicado: (2020)

The use of everolimus in renal-transplant patients
por: Pascual, Julio
Publicado: (2009)

The Role of Everolimus in Renal Cell Carcinoma
por: Meskawi, Malek, et al.
Publicado: (2015)

Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy
por: Buti, Sebastiano, et al.
Publicado: (2016)

No association between major congenital malformations and exposure to Kampo medicines containing rhubarb rhizome: A Japanese database study
por: Suzuki, Satoko, et al.
Publicado: (2023)

A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
por: Takahashi, Shunji, et al.
Publicado: (2019)

Clinical predictors of the estimated glomerular filtration rate 1 year after radical nephrectomy in Japanese patients
por: Shimada, Shuichi, et al.
Publicado: (2017)

Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2(+/−) Mice Is Superior to Everolimus Alone()
por: Yang, Jian, et al.
Publicado: (2017)

Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma
por: Li, Siming, et al.
Publicado: (2014)

Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
por: Huijts, Charlotte M., et al.
Publicado: (2018)

Everolimus-induced activation of latent Mycobacterium tuberculosis infection in a patient with metastatic renal cell carcinoma
por: Jeon, So-Yeon, et al.
Publicado: (2017)

A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer
por: Lolli, Cristian, et al.
Publicado: (2017)

Role of everolimus in the treatment of renal cell carcinoma
por: George, Saby, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ujui2qrosa6nrhhrujtl6c1b43